AssetMemo

Preview Research free. Sign in to unlock 3 full asset or company pages every day, no card needed.Sign in to unlock this page

Company profile

Grünenthal GmbH

Privately held: no public share price

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Capsaicin (Qutenza)
Approved
TRPV1 (transient receptor potential vanilloid 1) channelSmall molecule
Diabetic Peripheral Neuropathic Pain
Tapentadol
Approved
Mu-opioid receptor and norepinephrine transporter (NET)Small molecule
Diabetic Peripheral Neuropathic Pain

Upcoming events

Unlock with Research ↗
Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Unlock with Research ↗
Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share prices are end-of-day closes, delayed by 24 hours.